Cycle on Jul 25, 2026

I will start by listing the active threads and reading the existing notes for this topic to see what is currently being tracked and what needs updating or resolving.

I will read the existing notes for the topic to see what prior findings we have recorded and their exact slugs and content.

I see we have several active watches, and some are scheduled around now (late July 2026). Let's review the critical dates: - Today's date: July 25, 2026 - Watch `019f67f8-1a98-7a61-a210-07071f61b308`: "FDA filing acceptance and PDUFA date for Saol's SL1009", fire date 2026-07-30 - Watch `019f1ab8-f9db-7f35-b537-f4db6a56efeb`: "FDA finalization and launch of Expedited-IND Pilot Program", comment period closed July 22, 2026 - Watch `019f0620-007b-7dab-87b4-0363a2496ea1`: "FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma", target action date August 2, 2026, AdCom scheduled late July 2026 - Watch `019f061f-f34a-7079-a276-d216329928b2`: "FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy", scheduled for July 29, 2026 - Watch `019ef184-1ea4-72e1-a12e-ed934bbac64e`: "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis", expected in mid-2026 - Watch `019ec855-8c35-71a4-b33b-90db344bf45d`: "FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant", expected early August 2026, 60 days post-submission - Watch `019f776d-f69b-75cf-93b1-ae8e6c95e559` and `019f2f50-7f4d-7361-8f05-cdf170c2d727`: New Zealand and Australia H5N1 transmission to poultry or wildlife sanctuaries. Let's do some web searches to see if there are updates on any of these watches, or generally in science/health (e.g. FDA decisions, drug trials, outbreaks, space/biology breakthroughs) since July 20-25, 2026. Let's start by searching for Capricor's deramiocel, Replimune's RP1, Saol's SL1009, and other recent health/science news from the last week. I will use `web_search` with `sort="recent"`.

Let's fetch the Federal Register page or one of the articles to see details about the upcoming AdComs. Wait, let's search for Replimune's RP1 advisory committee and PDUFA date. Let's do a search on that.

Let's fetch the article "FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions" on yahoo finance or stocktwits. Let's do a search on Yahoo Finance for that article. Or Merlin Trader. Let's do a search for the exact URL or content of `https://finance.yahoo.com/healthcare/articles/fda-showdown-week-capr-nrxp-003040838.html` or similar. Wait, we can fetch `https://oncodaily.com/technology/replimune-548332` or `https://www.merlintrader.com/weekly-market-recap-july20-24-week-ahead-july27-31-2026/` or `https://finance.yahoo.com/healthcare/articles/fda-showdown-week-capr-nrxp-003040838.html`. Let's try to fetch `https://oncodaily.com/technology/replimune-548332` first. Or search for "FDA Showdown Week: CAPR, NRXP, REPL And MRNA" to see what other sources have it. Let's fetch `https://oncodaily.com/technology/replimune-548332`. Oh, let's also fetch `https://finance.yahoo.com/healthcare/articles/fda-showdown-week-capr-nrxp-003040838.html` if possible, but let's see if we can fetch `https://oncodaily.com/technology/replimune-548332` first. Wait, let's check `status_code` of web_fetch. Let's fetch `https://oncodaily.com/technology/replimune-548332`. Let's state intent. I will fetch the OncoDaily article to understand the context of the upcoming Replimune RP1 FDA advisory committee review.

This is a spectacular and highly detailed article on Replimune's RP1! It highlights the upcoming late July ODAC meeting (scheduled for July 30, 2026, as noted in the search results: "upcoming FDA Advisory Committee meeting on July 30", and "advisory committee meeting set for July 30, 2026") and the PDUFA date of August 2, 2026. Wait, let's look for the FDA briefing documents for both Capricor's deramiocel (scheduled for July 29, 2026) and Replimune's RP1 (scheduled for July 30, 2026). Under FDA rules, briefing documents are typically released 2 days prior to the advisory committee meeting. Let's see: today is July 25, 2026. The meeting for Capricor is July 29, 2026. The briefing documents for Capricor's deramiocel should be released on or around July 27, 2026. Let's check if they have been released early or if there are any previews of the briefing documents. Let's do a search on Capricor's deramiocel briefing documents.

Excellent! This is extremely helpful. This confirms: - Capricor's deramiocel: AdCom is July 29, 2026. The PDUFA target action date is August 22, 2026 (for DMD-associated cardiomyopathy). - Replimune's RP1: AdCom is July 30, 2026. The PDUFA target action date is August 2, 2026 (for advanced melanoma). Let's check on Saol's SL1009 (sodium dichloroacetate, or DCA) in pyruvate dehydrogenase complex deficiency (PDCD). Let's do a search on Saol and SL1009 to see if the FDA has accepted the resubmitted NDA and set a PDUFA date. Let's remember the watch is `019f67f8-1a98-7a61-a210-07071f61b308` (expected by late July 2026). Let's see if there's any news.

Wait, let's search for `Saol "SL1009"` or `"Saol Therapeutics" SL1009` or `Saol "sodium dichloroacetate"` with no freshness limit or with `freshness="month"` to see if there's any recent news on Saol's resubmitted NDA for SL1009. Let's do that.

Ah, Saol's resubmission was announced in early July (approx 2 weeks ago). Let's see if the FDA has accepted it or if there is a newer update. The resubmission was on or around July 10, 2026. The FDA has up to 30 days to review a resubmission (if it's a Class 1 or Class 2 resubmission, Class 1 is 2 months, Class 2 is 6 months). Wait, the watch description says: "Monitor the FDA's decision to accept Saol Therapeutics' resubmitted NDA for SL1009 (DCA) ... expected by late July 2026." Let's do a search on `Saol SL1009 accept` or `Saol SL1009 acceptance` or `Saol "PDUFA"` to see if there are any updates in the last few days. If not, it means the FDA has not yet announced the acceptance of the resubmission (which would be expected by early August, 30 days after the July 10 resubmission). Let's check BioSpace or PR Newswire. Let's do a quick search.

Okay, so there is no new announcement of FDA filing acceptance or a PDUFA date for SL1009 yet. The resubmission was announced on July 10, 2026. The FDA typically has up to 30 days (which would be around August 9, 2026) to make a filing acceptance decision. So this watch remains open and pending. Now let's check on other watches. Let's search for MoonLake's sonelokimab Phase 3 IZAR-1 trial readout in psoriatic arthritis (PsA) (expected in mid-2026, watch ID `019ef184-1ea4-72e1-a12e-ed934bbac64e`). Let's search for `MoonLake sonelokimab IZAR-1` or `sonelokimab psoriatic arthritis Phase 3` to see if there's any recent news.

Okay, so MoonLake's sonelokimab Phase 3 IZAR-1 trial readout in PsA is expected in Q3 2026, and the BLA submission for sonelokimab in HS is planned for September 2026. This watch is also still open and pending. Let's check on other watches. Let's search for Belite Bio's tinlarebant NDA acceptance and PDUFA date (expected early August 2026, watch ID `019ec855-8c35-71a4-b33b-90db344bf45d`). Let's search for `Belite Bio tinlarebant NDA accept` or similar.

Great! Belite Bio completed its rolling NDA submission in June 2026. This means the 60-day filing review window is still active, and an FDA decision to accept the filing and assign a PDUFA date is expected in early August 2026. This watch remains active. Now let's check on the FDA's proposed rule RIN 0910-AJ16 on Complete Response Letter public disclosure and the citizen petition (Docket FDA-2026-P-4369). Let's search for `Complete Response Letter public disclosure` or `FDA citizen petition CRL` or `Docket FDA-2026-P-4369` or `RIN 0910-AJ16` to see if there are any new filings or comments or decisions. Let's do a search.

Wow! Let's fetch `https://www.pharmavoice.com/news/whats-in-the-fdas-latest-batch-of-rejection-letters/825923/` and `https://www.biospace.com/fda/fda-freezes-crl-trove-as-radical-transparency-push-hits-speedbump`. This is extremely relevant to our existing note `fda-crl-public-disclosure-policy` ("FDA Resumes Controversial Complete Response Letter Transparency Policy After Three-Month Pause"). Let's fetch `https://www.biospace.com/fda/fda-freezes-crl-trove-as-radical-transparency-push-hits-speedbump` first to see the latest update. I will state my intent and then fetch the BioSpace article.

This is extremely useful and clarifies the current state of the CRL transparency policy. Let's do a search on the other recent news. Let's check the other article: `https://www.pharmavoice.com/news/whats-in-the-fdas-latest-batch-of-rejection-letters/825923/`. Let's fetch it to see what specific CRLs are highlighted as recent. This will help us ground our updates. I will state my intent and then fetch the PharmaVoice article.

This is an exceptional set of updates! This allows us to update the note `fda-crl-public-disclosure-policy` with the latest developments (that the FDA did NOT freeze the CRL trove, but actually confirmed they are continuing proactive publication under Secretary Kennedy's leadership, and that 14 new CRLs were posted on July 10, including Ascelia Pharma's Orviglance and Galderma's RelabotulinumtoxinA). Let's check if there are other major drug approvals or trial readouts in the last week. Let's search for "FDA approval" or "Phase 3 results" or "outbreak" with `recent=true` or `sort="recent"` and `freshness="week"`. Let's do a search on recent health/science news.

Ah! The web_search budget for this cycle is spent. That's perfectly fine; we have plenty of high-quality, extremely recent, and detailed primary facts from our searches and fetches. Let's organize our findings and updates: 1. **Update on FDA's Complete Response Letter public disclosure policy** (`fda-crl-public-disclosure-policy`): - The FDA has officially confirmed that it did **not** freeze or permanently pause its proactive publication of Complete Response Letters (CRLs), contrary to reports earlier in July. - HHS Press Secretary Emily Hilliard confirmed that under Secretary Robert F. Kennedy, Jr.'s leadership, the FDA remains dedicated to "radical transparency," stating: *"Under Secretary Kennedy’s leadership, FDA remains committed to increasing transparency through the proactive release of Complete Response Letters (CRLs)."* - On July 10, 2026, the FDA released a new batch of 14 CRLs. - This batch included rejections for Ascelia Pharma's oral MRI contrast agent Orviglance (detailing clinical trial reader training and bias concerns) and Galderma's RelabotulinumtoxinA (detailing facility deficiencies and analytical method optimization). - The citizen petition filed in April by an unnamed pharmaceutical company (Docket No. FDA-2026-P-4369-0001) challenging the legality of the proactive publishing continues to be evaluated by the FDA, with a formal response deadline of October 17, 2026. - The FDA's proposed rule RIN 0910-AJ16 to permanently codify the disclosure policy is still active. 2. **Update on Cyclospora Outbreak** (`cyclosporiasis-michigan-multistate-outbreak-2026`): - The domestic outbreak of the foodborne parasite *Cyclospora cayetanensis* has escalated, with the CDC reporting 4,173 laboratory-confirmed domestic cases as of late July 2026. - The investigation continues to focus on contaminated shredded iceberg lettuce from Taylor Farms. The Taylor Farms CEO broke silence, and a class-action lawsuit has been filed. - Furthermore, the FDA has identified a brand-new, separate Cyclospora outbreak linked to an unspecified product, which has sickened dozens of people (72 cases reported) and is under active traceback investigation. - This adds pressure to the CDC and FDA under Secretary Robert F. Kennedy, Jr. 3. **Advisory Committee Meetings for Capricor's Deramiocel and Replimune's RP1** (`fda-regulatory-pivot-advisory-committees-capricor-replimune`): - The upcoming week (late July 2026) is a critical "showdown week" for the FDA's newly revived advisory committee process. - **Capricor's deramiocel:** Cellular, Tissue, and Gene Therapies Advisory Committee meeting is scheduled for **July 29, 2026**, to review the BLA for deramiocel in Duchenne muscular dystrophy (DMD) cardiomyopathy. Briefing documents are expected to be released around July 27, 2026. The PDUFA target action date is August 22, 2026. - **Replimune's RP1:** Oncologic Drugs Advisory Committee (ODAC) meeting is scheduled for **July 30, 2026**, to review the resubmitted BLA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma that has progressed on anti-PD-1 therapy. The PDUFA target action date is August 2, 2026. - These back-to-back public panels show the FDA's willingness to adjudicate complex "contribution of effect" and clinical efficacy questions in an open, transparent forum following major patient advocacy mobilization. Let's double check if we have any other updates. We can update these three notes. Let's write them carefully. Let's first read the exact text of our existing notes for these three slugs so we can merge or update them correctly. We already retrieved the preview of the notes. Let's see: - Slug `fda-crl-public-disclosure-policy`: "The U.S. Food and Drug Administration (FDA) has resumed its controversial policy of publishing unapproved drug rejection letters, known as Complete Response Letters (CRLs), in real-time. On July 10,…" - Slug `cyclosporiasis-michigan-multistate-outbreak-2026`: "The summer 2026 outbreak of the foodborne parasite *Cyclospora cayetanensis* has escalated into a major public health emergency, with national cases surging past 4,000. Michigan is at the epicenter…" - Slug `fda-regulatory-pivot-advisory-committees-capricor-replimune`: "The U.S. Food and Drug Administration (FDA) has executed a profound operational and regulatory correction, formally scheduling back-to-back advisory committee meetings for two prominent rare-disease…" Let's write updated versions of these three notes to reflect the latest developments. Let's start with `fda-crl-public-disclosure-policy`. Let's draft it. Wait! Let's check the rules for `write_note`: - Format: # <Title> <body> ## Sources - [Source Title](URL) — gloss - [Source Title](URL) — gloss - No YAML frontmatter. - Body must have 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from. - Slug must be stable. Let's write `fda-crl-public-disclosure-policy` first. We have a quote from Emily Hilliard: > "Under Secretary Kennedy’s leadership, FDA remains committed to increasing transparency through the proactive release of Complete Response Letters (CRLs)," HHS Press Secretary Emily Hilliard wrote to _BioSpace_ in an email. "Transparency and public confidence are central to FDA’s mission to protect public health, and the American people deserve clear, timely, and accurate information about the agency’s regulatory decisions." And we have information about the 14 new CRLs released on July 10, including Ascelia Pharma's Orviglance and Galderma's RelabotulinumtoxinA. Let's construct the note body for `fda-crl-public-disclosure-policy`. I will state my intent and then write the note.

Now let's update the Cyclospora outbreak note: `cyclosporiasis-michigan-multistate-outbreak-2026`. Let's see what the latest numbers and details are: - Total laboratory-confirmed domestic cases has reached 4,173. - Michigan is at the epicenter. - Taylor Farms CEO has broken silence, class-action lawsuit filed over contaminated shredded iceberg lettuce. - The FDA has identified a brand-new, separate Cyclospora outbreak with 72 cases and an unknown source under active traceback investigation. - HHS Secretary Robert F. Kennedy, Jr. defended the handling of the outbreak, which is testing federal food safety agencies. Let's write this note. I will state my intent first.

Excellent! Now let's update the note `fda-regulatory-pivot-advisory-committees-capricor-replimune` ("The Post-Makary FDA Pivot: Back-to-Back AdComs Confirmed for Capricor's Deramiocel and Replimune's RP1"). Let's review the details: - Capricor's deramiocel: Cellular, Tissue, and Gene Therapies Advisory Committee meeting is scheduled for July 29, 2026. This reviews the BLA for deramiocel in Duchenne muscular dystrophy (DMD) cardiomyopathy. The FDA action goal (PDUFA) date is August 22, 2026. Briefing documents are expected on July 27, 2026. - Replimune's RP1 (vusolimogene oderparepvec): Oncologic Drugs Advisory Committee (ODAC) meeting is scheduled for July 30, 2026. This reviews the resubmitted BLA for RP1 in combination with nivolumab for advanced melanoma that has progressed on anti-PD-1 therapy. The PDUFA target action date is August 2, 2026. - This is a critical "showdown week" for the FDA's newly revived advisory committee process. - For Replimune, this is a rare third FDA review. The two prior CRLs (July 2025 and April 2026) were based on "contribution of effect" concerns (whether a single-arm study could show RP1 adds benefit on top of nivolumab). - The patient community (AIM at Melanoma, Melanoma Research Alliance, Melanoma Research Foundation) mobilized a massive advocacy campaign that influenced the FDA's decision to accept the third resubmission and schedule the AdCom. - The global, randomized Phase 3 IGNYTE-3 trial (enrolling ~400 patients) is ongoing as the confirmatory trial. Let's write this updated note. I will state my intent first.

This is wonderful! We have successfully updated three crucial notes with extremely recent, grounded, and highly detailed primary facts. Let's review the active threads to see if we can resolve any. Let's see: - Thread `019f0620-007b-7dab-87b4-0363a2496ea1`: "FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma" -> This thread is still active because the meeting is July 30, 2026 and PDUFA is August 2, 2026. This is a watch thread (one_shot), so we don't resolve it yet. We will resolve it or record an event when the meeting or decision happens. - Thread `019f061f-f34a-7079-a276-d216329928b2`: "FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy" -> This meeting is July 29, 2026. This watch thread is also still active and pending the meeting. - Thread `019f67f8-1a98-7a61-a210-07071f61b308`: "FDA filing acceptance and PDUFA date for Saol's SL1009" -> This is still pending (the FDA has up to 30 days from the July 10 resubmission, which is around August 9, 2026). - Thread `019f1ab8-f9db-7f35-b537-f4db6a56efeb`: "FDA finalization and launch of Expedited-IND Pilot Program" -> Still pending. - Thread `019f9650-e4d1-7acf-a7d3-9378517505ec`: "FDA response to CRL public disclosure citizen petition (Docket FDA-2026-P-4369)" -> Still pending. Since we updated the notes but none of the watch triggers have fully resolved yet (they are all scheduled for late July or August), we do not call `resolve_thread` or `record_event` on them. They will remain open as watches for future cycles to track and resolve when they fire. Let's finish the cycle now. I will state my intent and call `finish_cycle`.

I have successfully completed the research cycle for this topic. Here is a summary of the findings and updates recorded in this cycle: 1. **FDA's Complete Response Letter (CRL) Public Disclosure Policy (`fda-crl-public-disclosure-policy`)**: - Updated to reflect the FDA's official confirmation to *BioSpace* that it did **not** freeze or permanently pause its proactive publication of unapproved drug rejection letters, despite earlier reports. - HHS Press Secretary Emily Hilliard confirmed that under Secretary Robert F. Kennedy, Jr.'s leadership, the FDA remains fully committed to "radical transparency." - On July 10, 2026, the FDA released a new batch of 14 CRLs, including rejections for **Ascelia Pharma's Orviglance** (detailing clinical trial reader training and bias concerns) and **Galderma's RelabotulinumtoxinA** (detailing facility deficiencies and analytical method optimization). - The citizen petition filed in April by an unnamed pharmaceutical company (Docket No. FDA-2026-P-4369-0001) challenging the policy continues to be evaluated by the FDA, with a formal response deadline of **October 17, 2026**. 2. **National Cyclospora Outbreak (`cyclosporiasis-michigan-multistate-outbreak-2026`)**: - Updated to reflect that the domestic outbreak of the foodborne parasite *Cyclospora cayetanensis* has surged to **4,173 laboratory-confirmed cases**, with Michigan at the epicenter. - The primary outbreak is epidemiologically linked to shredded iceberg lettuce supplied by Taylor Farms. The Taylor Farms CEO has broken silence, and a class-action lawsuit has been filed. - The FDA and CDC also detected a **brand-new, separate Cyclospora outbreak** in late July 2026, which has sickened **72 individuals** and is linked to an unspecified product currently under active traceback investigation. - HHS Secretary Robert F. Kennedy, Jr. recently defended the federal government's handling of the outbreak amid scrutiny of food safety agency funding. 3. **FDA "Showdown Week" for Revived Advisory Committees (`fda-regulatory-pivot-advisory-committees-capricor-replimune`)**: - Updated to detail the exact timelines and scientific contexts for the back-to-back panels scheduled for the final week of July: - **Capricor's Deramiocel (DMD Cardiomyopathy):** Reviewed by the Cellular, Tissue, and Gene Therapies Advisory Committee on **July 29, 2026**. Briefing documents are expected on July 27, 2026, ahead of the PDUFA target action date of **August 22, 2026**. - **Replimune's RP1 (Advanced Melanoma):** Reviewed by the Oncologic Drugs Advisory Committee (ODAC) on **July 30, 2026**. This marks an exceptionally rare third FDA review, driven by a massive patient advocacy mobilization after the FDA's second rejection in April 2026. The PDUFA target action date is **August 2, 2026**. All watches remain active and will be monitored in future cycles to record events as these regulatory decisions and trial readouts unfold.